



HAL
open science

De novo mutations in HCN1 cause early infantile epileptic encephalopathy

Caroline Nava, Carine Dalle, Agnès Rastetter, Pasquale Striano, Carolien de Kovel, Rima Nabbout, Claude Cances, Dorothée Ville, Eva Brilstra, Giuseppe Gobbi, et al.

► To cite this version:

Caroline Nava, Carine Dalle, Agnès Rastetter, Pasquale Striano, Carolien de Kovel, et al.. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. *Nature Genetics*, 2014, 46 (6), pp.640-645. 10.1038/ng.2952. hal-01710614

HAL Id: hal-01710614

<https://hal.univ-lorraine.fr/hal-01710614>

Submitted on 3 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

De novo mutations in HCN1 cause early infantile epileptic encephalopathy

Caroline Nava,^{1,4,24} Carine Dalle^{5,24}, Agnès Rastetter¹, Pasquale Striano^{6,23}, Carolien G.F. de Kovel⁷, Rima Nababout^{8,9}, Claude Cancès¹⁰, Dorothee Ville¹¹, Eva H. Brilstra⁷, Giuseppe Gobbi¹², Emmanuel Raffo¹³, Delphine Bouteiller¹⁴, Yannick Marie¹⁴, Oriane Trouillard^{1,3,4}, Angela Robbiano¹⁵, Boris Keren¹⁶, Dahbia Agher¹, Emmanuel Roze¹⁻³, Suzanne Lesage¹⁻³, Aude Nicolas¹⁻³, Alexis Brice¹⁻⁴, Michel Baulac¹⁻³, Cornelia Vogt¹⁷, Nady El Hajj¹⁷, Eberhard Schneider¹⁷, Arvid Suls^{18,19,23}, Sarah Weckhuysen^{18,19,23}, Padhraig Gormley^{20,23}, Anna-Elina Lehesjoki^{21,23}, Peter De Jonghe^{18,19,23}, Ingo Helbig^{22,23}, Stéphanie Baulac^{1-3,23}, Federico Zara^{15,23}, Bobby P.C. Koeleman^{7,23}, EuroEPINOMICS RES consortium, Thomas Haaf¹⁷, Eric LeGuern^{1-4,23}, and Christel Depienne^{1,3,17,23}

¹ Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 975, Institut du cerveau et de la moelle épinière (ICM), Hôpital Pitié-Salpêtrière, Paris, France. ² CNRS 7225, Hôpital Pitié-Salpêtrière, Paris, France. ³ Université Pierre et Marie Curie-Paris-6 (UPMC), UMR_S 975, Paris, France. ⁴ AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique, Unité Fonctionnelle de Neurogénétique moléculaire et cellulaire, Paris, France. ⁵ ICM, Institut du cerveau et de la moelle épinière, Plateforme d'électrophysiologie, Paris, France. ⁶ Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova and Gaslini Institute, Genova, Italy. ⁷ Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. ⁸ Department of Pediatric Neurology, Centre de Référence Epilepsies Rares, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. ⁹ Institut National de la Santé et de la Recherche Médicale (INSERM) U663, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Paris, France. ¹⁰ Service de neurologie pédiatrique, Hôpital des enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. ¹¹ Service de neurologie pédiatrique, Hôpital Femme Mère Enfant, CHU de Lyon, Bron, France. ¹² Child Neurology Unit, IRCCS Institute of Neurological Sciences of Bologna, Bologna, Italy. ¹³ Service de neuropédiatrie, Hôpital d'enfant de Brabois, CHU de Nancy, Vandoeuvre Les Nancy, France. ¹⁴ ICM, Institut du cerveau et de la moelle épinière, plate-forme de génotypage et séquençage, Paris, France. ¹⁵ Laboratory of Neurogenetics, Department of Neurosciences, Gaslini Institute, Genova, Italy. ¹⁶ AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique, Unité fonctionnelle de cytogénétique, Paris, France. ¹⁷ Institut für Humangenetik, Universität Würzburg, Würzburg, Germany. ¹⁸ Neurogenetics Group, Department of Molecular Genetics, VIB, Antwerp, Belgium. ¹⁹ Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ²⁰ Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, United Kingdom. ²¹ Folkhälsan Institute of Genetics; Research Programs Unit, Molecular Neurology and Neuroscience Center, University of Helsinki, Helsinki, Finland. ²² Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany. ²³ EuroEPINOMICS RES consortium.

²⁴ These authors contributed equally to the study

Correspondence should be addressed to C.De. (christel.depienne@upmc.fr) or E.L.G. (eric.leguern@psl.aphp.fr).

Summary

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels contribute to cationic I_h current in neurons and regulate the excitability of neuronal networks. Studies in rodent models have shown that the *Hcn1* gene plays a key role in epilepsy, but clinical evidence implicating *HCNI* mutations in human epilepsy is lacking. We carried out exome sequencing for parent-offspring trios with fever-sensitive intractable epileptic encephalopathy, leading to the discovery of two *de novo* missense *HCNI* mutations. The screening of follow-up cohorts comprising 157 patients in total identified four additional amino-acid substitutions. Patch-clamp recordings of I_h currents in cells expressing WT or mutant human HCN1 channels revealed that the mutations had striking, but divergent effects on homomeric channels. Patients with mutations had clinical features resembling those of Dravet syndrome, with progression toward atypical absences, intellectual disability and autistic traits. These findings provide clear evidence that *de novo* *HCNI* point mutations cause a recognizable early-onset epileptic encephalopathy in humans.

Early infantile epileptic encephalopathies (EIEEs) are mostly sporadic disorders characterized by recurrent seizures during the neonatal or infantile periods, with impaired cognitive and motor development. At least 15 different genetically determined forms of EIEE have been recognized^{1,2}. EIEEs typically result from *de novo* dominant mutations in a single autosomal gene, although autosomal recessive and X-linked forms also exist. Dravet syndrome, an intractable epilepsy generally occurring during the first year of life, is the prototype condition: seizures are initially febrile and prolonged, and polymorphic afebrile seizures appear later in the course of the disease. Cognitive and motor development progressively slows, progressing toward intellectual disability (ID)³. Dravet syndrome is mostly caused by *de novo* mutations of *SCN1A*, encoding the neuronal voltage-gated sodium $\alpha 1$ ($Na_v1.1$) channel^{4,5}. This syndrome overlaps clinically with *PCDH19*-related epilepsy, an X-linked disorder also associating febrile and afebrile seizures and variable degrees of ID, but expressed only in heterozygous females^{6,7}.

In this study, we carried out whole-exome sequencing on 39 parent-offspring trios including probands with EIEE resembling Dravet syndrome, without *SCN1A* and *PCDH19* mutations. Informed consent was obtained from the families and genetic studies were approved by local ethics committees. The analysis of exome data revealed heterozygous *de novo* mutations (c.299C>T, p.Ser100Phe and c.1201G>C, p.Asp401His) of *HCNI* (NM_021072.2) in two female probands, one French and the other Italian. We then screened 95 additional patients with fever-sensitive EIEE (French cohort) for mutations in *HCNI* coding regions, by amplicon-based pyrosequencing. Three female patients were each found to have a previously unknown nonsynonymous variant (c.140G>T, p.Gly47Val; c.814T>C, p.Ser272Pro; c.890G>C, p.Arg297Thr) in the heterozygous state. The sequencing of available parental DNA showed that p.Ser272Pro and p.Arg297Thr also occurred *de novo*. In parallel, the sequencing of several genes, including *HCNI*, in a Dutch follow-up cohort comprising 62 patients identified the *de novo* c.835C>T (p.His279Tyr) substitution in a male patient. In total, six different heterozygous missense mutations, all confirmed by Sanger sequencing and absent from databases (HapMap, 1000 Genomes, dbSNP137, Exome variant server) were identified in *HCNI* (Fig. 1a). *De novo* occurrence was confirmed for the five mutations for which inheritance could be investigated. The pathogenicity of Gly47Val remained uncertain due to the unavailability of parental DNA.

All patients had similar clinical features including seizures beginning at ages of 4 to 13 months and the combination of febrile and afebrile polymorphic seizures, including hemiclonic and generalized seizures. These features were initially suggestive of Dravet syndrome, but with

a different progression over time. Atypical absences, with or without myoclonic jerks, and focal seizures became predominant in the oldest patients. All patients had mild to severe ID and major behavioral disturbances, including autistic traits (Table 1, Supplementary Table 1).

HCN1 tolerates little functional variation, as only a few missense variants are present in control populations (Supplementary Fig. 1, Supplementary Table 2). Copy number variants (CNV) encompassing *HCN1* exons have been reported in healthy and intellectually disabled individuals, at similar low frequencies (Supplementary Table 3)⁸⁻¹⁰. We recently identified a deletion spanning exon 4 of *HCN1* in a female with sporadic ID and autism spectrum disorder (ASD) but no epilepsy¹¹. Further analyses showed that this deletion was inherited from her asymptomatic father (Supplementary Fig. 2). No second pathogenic mutation was found in the proband, so an autosomal recessive disorder was unlikely. Intragenic *HCN1* deletions alone therefore seem to be insufficient to cause ID and ASD, although they possibly contribute to these disabilities. HCN1 dysfunction may therefore result in a spectrum of phenotypes, ranging from haploinsufficiency as an inherited risk factor for neurodevelopmental disorders to *de novo* mutations causing EIEE.

HCN1 is one of four genes encoding hyperpolarization-activated cyclic nucleotide-gated channels (HCN) with different biophysical properties, expressed in the heart and brain¹²⁻¹⁴. In neurons, HCN1 is mainly localized in dendrites¹⁵. HCN subunits have six transmembrane domains and functional channels consist of four subunits. HCN channels are permeable to Na⁺ and K⁺ ions and are activated by membrane hyperpolarization. In the brain, they conduct the I_h current, which contributes to spontaneous rhythmic activity and the stabilization of neuronal membrane potential against excitatory or inhibitory inputs¹⁶. The mutations identified here affect strongly conserved amino acids, except for glycine 47 and, to a lesser extent, serine 100, which are located in less well conserved domains of HCN1 (Supplementary Fig. 3). The amino acids affected are located in different parts of the channel, but all are intracellular, and four are located close to domains forming the channel pore (Fig. 1b), in particular in the S4-S5 linker, involved in voltage-dependent gating¹⁴.

We assessed the functional consequences of *de novo* mutations identified in EIEE patients, by carrying out patch-clamp recordings on CHO-K1 cells expressing WT or mutant human HCN1 channels. Voltage-dependent, slowly activating inward currents were recorded in cells expressing the WT, S100F, H279Y and D401H HCN1 proteins, consistent with the expression of functional channels (Fig. 2a and 2b). These three mutations had major effects on channel gating (Fig. 2c). The half-activation voltage (V_{1/2}) for the S100F and H279Y channels was depolarized by ~27 mV and ~17 mV, respectively, with respect to the WT HCN1. D401H HCN1 was activated at higher positive voltages, due to a 46 mV shift of the activation curve. The S100F and D401H mutations also resulted in significantly faster activation than for WT HCN1 (Fig. 2d). Furthermore, all three mutations displayed a slower deactivation compared to the WT channel (Fig. 2e). Finally, the S100F mutation also significantly shifted the reversal potential to negative voltage (Supplementary Fig. 4). Altogether, these results indicate that S100F, H279Y and D401H lead to a gain of function (GoF) of homotetrameric HCN1 channels. By contrast, no I_h current was recorded for cells expressing the S272P and R297T channels (Fig. 2a, Supplementary Fig. 5). These mutant channels were present in lower amounts in cell lysates and at the plasma membrane compared to the WT channels, but similar reduced protein expression, probably due to the instability of the mutated proteins, was also observed for other mutants retaining substantial channel activity, such as S100F (Supplementary Fig. 6), indicating that the loss of function (LoF) were specific to these amino acid changes.

To gain further insights into the mechanisms by which mutations with apparent divergent impacts cause similar phenotypes and to mimic the heterozygous state of the mutations in the patients, we performed co-expression of WT and mutant HCN1 proteins. Strikingly, R297T HCN1 and, to a lesser extent, S100F and S272P HCN1 but not D401H showed a dominant

negative effect on the WT form, by decreasing the current density of heteromeric channels (Fig. 3). These results support the hypothesis that the *de novo* HCN1 mutations identified in this study mostly lead to GoF or dominant negative effects rather than LoF.

Ih current regulates neuronal excitability and the dendritic integration of synaptic potentials in individual neurons and neuronal networks^{13,14,17,18}. HCN1 and HCN2 are the main HCN isoforms expressed in the brain and contributing to this current. HCN1 is predominantly expressed in the neocortex and hippocampus, whereas HCN2 is expressed more evenly, but slightly more strongly in the thalamus than elsewhere^{19,20}. Acquired Ih current dysfunction, due to abnormal *Hcn1* expression or distribution in particular, has been shown to play a crucial role in epileptogenic processes in rodents^{14,16,21,22}. *HCN1* defects were then predicted to contribute to epilepsy in humans as well, and *HCN1* was screened for mutations in patients with idiopathic generalized epilepsy (IGE)^{23,24}. Our results finally provide the first evidence implicating *HCN1* mutations in human epilepsy and show that the associated phenotype is more severe than in the patients with IGE that were previously screened.

Functional studies confirmed that the *de novo* mutations had major impacts on HCN1 function and mostly lead to GoF. However, the precise mechanisms by which mutations cause EIEE in humans remain to be clarified. The observations for LoF mutations were consistent with previous findings describing a decrease in *HCN1* expression occurring very early in epileptogenesis in seizure-induced or spontaneous epileptic rat models²⁵⁻²⁹, and an upregulation of HCN channel function by some antiepileptic drugs^{30,31}. However, rare heterozygous deletions encompassing *HCN1* exons exist in non-epileptic individuals, and *Hcn1*^{-/-} mice have motor learning and memory deficits³² and a higher susceptibility to induced seizures^{33,34}, but display no spontaneous seizures³². These observations suggest that *HCN1* haploinsufficiency, in contrast to point mutations altering channel function, can be functionally tolerated by the developing brain and that HCN1 deficiency promotes neuronal excitability but is insufficient *per se* for seizure development. Proteins with amino acid substitutions are predicted to be present in the cells of patients, with the HCN subunits assembling into functional homo- or heterotetramers¹³. Thus, missense mutations may have dominant negative effects, interfering with the function of the remaining *HCN1* allele, as demonstrated for R297T and S272P, but also with that of *HCN2* in neurons in which they are co-expressed. Consistent with this hypothesis, *Hcn2*^{-/-} mice display spontaneous absence seizures^{35,36}, and a recessive loss-of-function mutation in *HCN2* was recently identified in one patient with IGE³⁷. Alternatively, both increases and decreases in Ih current may be pathological, since both the downregulation and upregulation of *HCN1* expression have been reported, depending on the epileptic rat model^{13,22}. Finally, *HCN1* mutations may have opposite (*i.e.* LoF or GoF) effects depending on the physiological context and cells in which they are expressed, as observed for Nav1.1 and Nav1.7^{38,39}.

In conclusion, this study provides further evidence of the crucial role of HCN1 and Ih current in human epilepsies. The phenotype of patients with *HCN1*-related encephalopathy, with initial fever-sensitive seizures progressing toward predominant absences and focal seizures, is consistent with HCN1 function and expression, and previous observations of HCN1 channelopathy in animal models of focal or absence epilepsies.

URLs.

HapMap, <http://hapmap.ncbi.nlm.nih.gov/>; 1000 Genomes, <http://www.1000genomes.org/>; dbSNP, <http://www.ncbi.nlm.nih.gov/SNP/>; Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (<http://evs.gs.washington.edu/EVS/>), <http://evs.gs.washington.edu/EVS/>; SIFT, <http://sift.jcvi.org/>; PolyPhen-2, <http://genetics.bwh.harvard.edu/pph2/>.

ACKNOWLEDGMENTS

We thank the patients and their family for their participation in this study, Dr. Juliane Stieber for providing a plasmid containing the human HCN1 cDNA, the International Parkinson's Disease Genomics Consortium (IPDGC) for giving access to the list of *HCN1* variants present in control and PD populations, Lies Van de Velde Boermans for genetic tests for *SCN1A* and *PCDH19* and tests on the parents, Mandy Nizard for patient selection, and Dr Guillaume Huguet and Prof. Thomas Bourgeron for helpful discussions. The research generating these results was funded by the University of Würzburg, Biocodex, *Fondation de France*, ERA-NET NEURON EUHFAUTISM, the "Investissements d'avenir" program ANR-10-IAIHU-06 (IHU-A-ICM), INSERM, AP-HP, the Eurocores program EuroEPINOMICS of the European Science Foundation, the Fund for Scientific Research Flanders (FWO) and University of Antwerp. P.S. and F.Z. thank the Genetics Commission of the Italian League Against Epilepsy (LICE) for their support. B.P.C.K. and C.d.K. were supported by The Netherlands National Epilepsy Fund. A.S. is a postdoctoral fellow of the FWO. C.N., A.B. and C.De. are members of the Bio-Psy Labex.

AUTHOR CONTRIBUTIONS

Clinical and genetic data. *French cohort:* C.De. and C.N. analyzed whole-exome sequencing data. C.N., A.Ra., D.A., D.B., Y.M., C.V., N.E.H., and E.S. contributed to pyrosequencing and/or Sanger sequencing and sequence analysis. B.K. and C.N. contributed to CNV analysis. O.T. performed qPCR. C.C., D.V., R.N. and E.Ra. phenotyped and sampled the patients and provided clinical information. E.Ro. was involved in patient selection. A.B., A.N. and S.L. contributed to variant analysis in populations from the IPDGC. S.B, M.B. and A.B contributed to study design and discussions. C.De. and E.L.G. supervised the projects related to EIEE, including cohort collection. C.De, E.L.G. and T.H designed this study. *Dutch cohort:* B.P.C.K and C.G.F.K designed the study and analyzed sequencing data. B.P.C.K. supervised the study. E.H.B. phenotyped and sampled the patients. *Italian patient:* This patient was included in the EuroEPINOMICS RES consortium. A.S., I.H. and P.G. analyzed whole-exome sequencing data. P.S, A.Ro. and F.Z. contributed to validation of exome sequencing data and supervision of the study. G.G. phenotyped the patient and provided clinical information. P.D.J., I.H., A.S., S.W., and A-E.L. designed the study and/or coordinated projects in the EuroEPINOMICS RES Consortium. **Functional studies** C.N. and A.Ra. performed the site-directed mutagenesis, cell transfections, immunohistochemistry and plasma membrane enrichment experiments. C.Da. performed the electrophysiology analysis and wrote the sections relating to electrophysiology. C.De supervised the collaborative study and drafted the manuscript. All authors critically revised the manuscript.

COMPETING FINANCIAL INTERESTS

The authors have no competing financial interests to declare.

REFERENCES

1. Depienne, C., Gourfinkel-An, I., Baulac, S. & LeGuern, E. Genes in infantile epileptic encephalopathies. (2012).
2. O'Brien, J.E. & Meisler, M.H. Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. *Front Genet* 4, 213 (2013).
3. Dravet, C. The core Dravet syndrome phenotype. *Epilepsia* 52 Suppl 2, 3-9 (2011).
4. Claes, L. et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* 68, 1327-32 (2001).

5. Depienne, C. et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. *J Med Genet* 46, 183-91 (2009).
6. Depienne, C. et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. *PLoS Genet* 5, e1000381 (2009).
7. Dibbens, L.M. et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. *Nat Genet* 40, 776-81 (2008).
8. Pinto, D. et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. *Nat Biotechnol* 29, 512-20 (2011).
9. Itsara, A. et al. Population analysis of large copy number variants and hotspots of human genetic disease. *Am J Hum Genet* 84, 148-61 (2009).
10. Cooper, G.M. et al. A copy number variation morbidity map of developmental delay. *Nat Genet* 43, 838-46 (2011).
11. Nava, C. et al. Prospective diagnostic analysis of copy number variants using SNP microarrays in individuals with autism spectrum disorders. *Eur J Hum Genet* 22, 71-8 (2014).
12. Santoro, B. et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. *Cell* 93, 717-29 (1998).
13. Benarroch, E.E. HCN channels: function and clinical implications. *Neurology* 80, 304-10 (2013).
14. Biel, M., Wahl-Schott, C., Michalakis, S. & Zong, X. Hyperpolarization-activated cation channels: from genes to function. *Physiol Rev* 89, 847-85 (2009).
15. Lorincz, A., Notomi, T., Tamas, G., Shigemoto, R. & Nusser, Z. Polarized and compartment-dependent distribution of HCN1 in pyramidal cell dendrites. *Nat Neurosci* 5, 1185-93 (2002).
16. Poolos, N.P. Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Ion Channelopathy in Epilepsy. (2012).
17. Kase, D. & Imoto, K. The Role of HCN Channels on Membrane Excitability in the Nervous System. *J Signal Transduct* 2012, 619747 (2012).
18. Nolan, M.F. et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. *Cell* 119, 719-32 (2004).
19. Santoro, B. et al. Molecular and functional heterogeneity of hyperpolarization-activated pacemaker channels in the mouse CNS. *J Neurosci* 20, 5264-75 (2000).
20. Bender, R.A. et al. Differential and age-dependent expression of hyperpolarization-activated, cyclic nucleotide-gated cation channel isoforms 1-4 suggests evolving roles in the developing rat hippocampus. *Neuroscience* 106, 689-98 (2001).
21. Chen, K. et al. Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability. *Nat Med* 7, 331-7 (2001).
22. Noam, Y., Bernard, C. & Baram, T.Z. Towards an integrated view of HCN channel role in epilepsy. *Curr Opin Neurobiol* 21, 873-9 (2011).
23. Dibbens, L.M. et al. Augmented currents of an HCN2 variant in patients with febrile seizure syndromes. *Ann Neurol* 67, 542-6 (2010).
24. Tang, B., Sander, T., Craven, K.B., Hempelmann, A. & Escayg, A. Mutation analysis of the hyperpolarization-activated cyclic nucleotide-gated channels HCN1 and HCN2 in idiopathic generalized epilepsy. *Neurobiol Dis* 29, 59-70 (2008).
25. Brewster, A. et al. Developmental febrile seizures modulate hippocampal gene expression of hyperpolarization-activated channels in an isoform- and cell-specific manner. *J Neurosci* 22, 4591-9 (2002).

26. Brauer, A.U. et al. Molecular and functional analysis of hyperpolarization-activated pacemaker channels in the hippocampus after entorhinal cortex lesion. *FASEB J* 15, 2689-701 (2001).
27. Jung, S. et al. Progressive dendritic HCN channelopathy during epileptogenesis in the rat pilocarpine model of epilepsy. *J Neurosci* 27, 13012-21 (2007).
28. Powell, K.L. et al. Decreases in HCN mRNA expression in the hippocampus after kindling and status epilepticus in adult rats. *Epilepsia* 49, 1686-95 (2008).
29. Kole, M.H., Brauer, A.U. & Stuart, G.J. Inherited cortical HCN1 channel loss amplifies dendritic calcium electrogenesis and burst firing in a rat absence epilepsy model. *J Physiol* 578, 507-25 (2007).
30. Surges, R., Freiman, T.M. & Feuerstein, T.J. Gabapentin increases the hyperpolarization-activated cation current I_h in rat CA1 pyramidal cells. *Epilepsia* 44, 150-6 (2003).
31. Munsch, T. & Pape, H.C. Upregulation of the hyperpolarization-activated cation current in rat thalamic relay neurones by acetazolamide. *J Physiol* 519 Pt 2, 505-14 (1999).
32. Nolan, M.F. et al. The hyperpolarization-activated HCN1 channel is important for motor learning and neuronal integration by cerebellar Purkinje cells. *Cell* 115, 551-64 (2003).
33. Santoro, B. et al. Increased seizure severity and seizure-related death in mice lacking HCN1 channels. *Epilepsia* 51, 1624-7 (2010).
34. Huang, Z., Walker, M.C. & Shah, M.M. Loss of dendritic HCN1 subunits enhances cortical excitability and epileptogenesis. *J Neurosci* 29, 10979-88 (2009).
35. Ludwig, A. et al. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. *EMBO J* 22, 216-24 (2003).
36. Chung, W.K. et al. Absence epilepsy in apathetic, a spontaneous mutant mouse lacking the h channel subunit, HCN2. *Neurobiol Dis* 33, 499-508 (2009).
37. DiFrancesco, J.C. et al. Recessive loss-of-function mutation in the pacemaker HCN2 channel causing increased neuronal excitability in a patient with idiopathic generalized epilepsy. *J Neurosci* 31, 17327-37 (2011).
38. Cestele, S., Schiavon, E., Rusconi, R., Franceschetti, S. & Mantegazza, M. Nonfunctional NaV1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects. *Proc Natl Acad Sci U S A* 110, 17546-51 (2013).
39. Rush, A.M. et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. *Proc Natl Acad Sci U S A* 103, 8245-50 (2006).

Additional collaborators of the EuroEPINOMICS RES CONSORTIUM

Rudi Balling²⁵, Nina Barisic²⁶, Hande S. Caglayan²⁷, Dana C. Craiu²⁸, Petia Dimova²⁹, Renzo Guerrini³⁰, Helle Hjalgrim³¹, Dorota Hoffman-Zacharska³², Johanna Jähn²², Karl Martin Klein³³, Vladimir Komarek³⁴, Roland Krause²⁵, Johannes R. Lemke³⁵, Holger Lerche³⁶, Carla Marini³⁰, Patrick May²⁵, Rikke S. Møller³¹, Hiltrud Muhle²², Aarno Paalotie³⁷, Deb Pal³⁸, Felix Rosenow³³, Kaja Selmer³⁹, José M. Serratos Fernandez⁴⁰, Sanjay Sisodiya⁴¹, Ulrich Stephani²², Katalin Sterbova³⁴, Tiina Talvik⁴², Sarah von Spiczak²², Yvonne Weber³⁶.

²⁵ Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. ²⁶ Department of Paediatrics, University of Zagreb, Medical School, University Hospital Centre Zagreb, Zagreb, Croatia. ²⁷ Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey. ²⁸ Pediatric Neurology Clinic II, Department of Neurology, Pediatric Neurology, Psychiatry, Neurosurgery, “Carol Davila” University of Medicine, and Pediatric Neurology Clinic, “Professor Doctor Alexandru Obregia” Clinical Hospital, Sector 4, Bucharest, Romania. ²⁹ Clinic of Child Neurology, St Naum University Hospital of Neurology and Psychiatry, Sofia, Bulgaria. ³⁰ Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer – University of Florence, Florence, Italy. ³¹ Danish Epilepsy Centre, Dianalund, Denmark. ³² Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland. ³³ Epilepsy Center Hessen, Department of Neurology, University Hospitals Marburg and Philipps-University Marburg, Marburg, Germany. ³⁴ Child Neurology Department, University Hospital Motol, Praha, Czech Republic. ³⁵ Division of Human Genetics, University Children's Hospital Inselspital, Bern, Switzerland. ³⁶ Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. ³⁷ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ³⁸ Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, United Kingdom. ³⁹ Department of Medical Genetics, Oslo University Hospital, Oslo, Norway and Institute of Medical Genetics, University of Oslo, Oslo, Norway. ⁴⁰ Epilepsy Unit, Neurology Service, Hospital Universitario Fundación Jiménez Díaz and Centro De Investigación Biomédica En Red De Enfermedades Raras (CIBERER), Madrid, Spain. ⁴¹ Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, United Kingdom. Epilepsy Society, Buckinghamshire, United Kingdom. ⁴² Department of Pediatrics, University of Tartu, and Department of Neurology and Neurorehabilitation, Children's Clinic, Tartu University Hospital, Tartu, Estonia.

ONLINE METHODS

Patients

We selected nine trios from the French cohort and 30 from the EuroEPINOMICS RES Consortium for exome sequencing. The inclusion criteria were: normal development before seizure onset, the presence of both febrile and afebrile seizures; the occurrence of polymorphic seizures (tonic-clonic, hemiclonic, myoclonic, absence and/or focal seizures); drug-resistant seizures or *status epilepticus*; developmental delay after seizure onset. All probands had tested negative for *SCN1A* mutations by sequencing and MLPA or Multiplex Amplicon Quantification (MAQ). The follow-up cohorts included 95 additional patients (41 male and 54 female patients) with fever-sensitive epileptic encephalopathy referred for early genetic testing of Dravet syndrome (La Pitié-Salpêtrière, Paris, France) and 62 patients with refractory epileptic encephalopathy and seizure onset within the first four years of age selected from the Dutch cohort (Utrecht, the Netherlands). Informed written consent was obtained from each individual or his/her parents before blood sampling. All experiments were performed in accordance with French guidelines and legislation.

Whole exome sequencing

Exome sequencing for patients N06 0565 and DRA-20 and their unaffected parents was performed by IntegraGen (Evry, France) or the Wellcome Trust Sanger Institute (Hinxton/Cambridge, UK), respectively, as described previously^{40,41}. Exons were captured from fragmented genomic DNA samples using the SureSelect Human All Exon 50Mb (Agilent Technologies) exome kit, and paired-end 75-base massively parallel sequencing was carried out on an Illumina HiSeq2000, according to manufacturers' protocols.

Analysis of whole exome data

Bioinformatics analyses were respectively done using the in-house pipeline developed by Integragen SA, as previously described^{40,41}, or as follows: sequencing reads passing quality filtering were aligned to the human reference genome (hg19) with Burrows-Wheeler Aligner (BWA)⁴². GATK⁴³ was used to recalibrate base quality scores, realign around indels, and mark duplicate reads. Independent variant calling was performed on the mapped reads with SAMtools⁴⁴ mpileup, GATK UnifiedGenotyper and Dindel⁴⁵. For annotating, comparing and filtering the data the GenomeComb⁴⁶ program was used. For the calling of *de novo* variants the DeNovoGear⁴⁷ program by Conrad and colleagues was used and double-checked by GenomeComb analysis.

Screening of *HCNI* by pyrosequencing

Exons and intron-exon junctions of *HCNI* (NM_021072.2) were analyzed by universal tailed amplicon sequencing (454 GS Junior System, Roche), with the exception of the amplicons 3 of exon 8 (8-3), which was screened by Sanger sequencing. Primer pairs (Supplementary Table 4) were designed for exon amplification by PCR; a second PCR was performed to incorporate a multiplex identifier and 454 adaptors, and emulsion PCR was carried out as described in the emPCR Amplification Method Manual (Roche).

Screening of candidate genes including *HCNI* by targeted capture and sequencing

Target enrichment of 340 selected candidate genes, including known epileptic encephalopathy genes and brain-expressed ion channels, was performed using glass slides (Agilent). Barcoded fragment libraries were equimolarly pooled and enriched using multiplexed targeted genomic enrichment. Sequencing was done on a SOLiD 5500 (Applied Biosystems). Alignment of reads on the human reference was performed with BWA, and additional bioinformatics steps including filtering for novel coding variants, were done using an in-house pipeline.

Sanger sequencing

Mutations identified by exome sequencing and pyrosequencing were validated by Sanger sequencing with the same primers as for pyrosequencing. Mutations found in patients were directly searched for in available parents by sequencing the corresponding exon. The amplicon 8-3, not covered by pyrosequencing, and exons covered less than 5X by pyrosequencing in some patients were screened by Sanger sequencing. Sequencing reactions were performed on G-50-purified PCR products, with the the BigDye Terminator kit. Sequencing products were run on an ABI Prism 3730 DNA Analyzer (Applied Biosystems) and the sequences obtained were analyzed with SeqScape 2.6 software (Applied Biosystems).

Parental testing

Parental testing was carried out with the AmpFI STR SGM plus Kit (Applied Biosystems), to exclude false paternity and DNA inversion, and to check that the mutation had occurred *de novo*.

***In silico* analyses**

The effects of mutations were interpreted with Alamut 2.2 (Interactive Biosoftware). The effects of predicted amino-acid substitutions were assessed with SIFT (<http://sift.jcvi.org/>) and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>).

Protein sequences of orthologs and paralogs of human HCN1 were retrieved from Uniprot (<http://www.uniprot.org/uniprot/>) and aligned using slow/accurate pairwise alignment defaults parameters with Clustalw (<http://www.genome.jp/tools/clustalw/>).

HCN1 expression plasmids

The plasmid containing the human *HCN1* cDNA was kindly provided by Dr. Juliane Stieber (Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany). The S100F, S272P, R297T, H279Y and D401H mutations were introduced into the cDNA with the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). All constructs were sequenced to ensure that no additional mutations were introduced.

Cell culture and transfection

CHO-K1 cells (CCL-61, ATCC) were cultured in HAM's F12 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were transiently cotransfected with cDNAs encoding the WT or a mutant human HCN1 (hHCN1) channel and pEGFP, with the NeonTM transfection system (Invitrogen), according to the manufacturer's instructions (medium without antibiotic): 1 µg of plasmid cDNA per dish was used for cotransfection, at a ratio of 50:1 (HCN1:pEGFP) for test experiments or with pEGFP alone for control experiments. For coexpression experiments, an equal ratio of WT and mutant (0.5µg of each plasmid) was used in the same conditions. Cells were plated at a density of 5.0×10^5 cells / 40-mm Petri dish for electrophysiological experiments and 2.0×10^6 cells / 100-mm Petri dish for western blot analysis. Cells were incubated for 24 h at 37°C, under an atmosphere containing 5% CO₂, before use.

Patch-clamp technique

Currents were recorded from GFP-expressing cells, with an Axopatch 200B amplifier and a Digidata 1440 analog/digital interface. Pipette resistance was 2-3 MΩ when filled with the intracellular solution containing 120 mM K aspartate, 10 mM NaCl, 10 mM KCl, 1 mM CaCl₂,

10 mM EGTA, 2 mM MgATP and 10 mM HEPES, adjusted to pH 7.2 with KOH. The extracellular solution contained 130 mM NaCl, 15 mM KCl, 0.5 mM MgCl₂, 1.8 mM CaCl₂, 10 mM glucose and 5 mM HEPES adjusted to pH 7.4 with NaOH. Series resistance was typically between 3 and 5 MΩ. Capacitive currents were cancelled and series resistance was compensated by 70 to 80 %. The liquid junction potential was not corrected. Whole-cell currents were low-pass Bessel-filtered at 1 kHz and digitized at 10 kHz. Data were acquired and analyzed with pClamp10 software. Electrophysiological recordings were carried out at room temperature (21-23°C). Whole-cell voltage-clamp mode was used to investigate the rate and voltage-dependence of channel activation. A series of test pulses, ranging from -140 to +40 mV in 10 mV increments from a holding potential of -20 mV, was applied to the cells for 1 second. Currents were measured in steady state at the end of the test pulses and were normalized with respect to cell capacitance. To obtain voltage-dependent activation curves, tail currents were measured at the fixed voltage of +50 mV immediately after each test pulse, normalized to maximum amplitude tail currents and then plotted against test voltage. Activation curves were fitted with a Boltzmann function:

$$I_t = I_t(\max) / [1 + \exp (V - V_{1/2})/k],$$

where I_t is the current amplitude of the tail current recorded for a given pre-pulse and $I_t(\max)$ is the maximum current amplitude of the tail current, V is voltage of the pre-pulse, $V_{1/2}$ is the half activation voltage and k is the slope factor.

Activation and deactivation time constant were obtained by fitting with a monoexponential function the steady-state current obtained on hyperpolarization at -110mV and the tail current at +10 mV following a conditioning prepulse at -130mV, respectively. Some currents presenting complex kinetic behaviour were not used for analysis. Analysis of raw data, graphical representations and statistical tests were performed with Origin software (OriginLab Corporation), using one-way ANOVA followed by Dunnett's *post hoc* test or two-way ANOVA followed by Bonferroni's post-hoc test for multiple comparison. The significance level was set at $p < 0.05$. All data are reported as means \pm SEM.

Additional references

40. Ishida, S. et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. *Nat Genet* 45, 552-5 (2013).
41. Suls, A. et al. De Novo Loss-of-Function Mutations in CHD2 Cause a Fever-Sensitive Myoclonic Epileptic Encephalopathy Sharing Features with Dravet Syndrome. *Am J Hum Genet* 93, 967-75 (2013).
42. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 26, 589-95 (2010).
43. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20, 1297-303 (2010).
44. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078-9 (2009).
45. Albers, C.A. et al. Dindel: accurate indel calls from short-read data. *Genome Res* 21, 961-73 (2011).
46. Reumers, J. et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. *Nat Biotechnol* 30, 61-8 (2012).
47. Conrad, D.F. et al. Variation in genome-wide mutation rates within and between human families. *Nat Genet* 43, 712-4 (2011).

Table 1 Genetic and clinical characteristics of the patients with *HCNI* mutations identified in this study

Family number	6	2	3	5	4	1
Patient origin	France	Italy	France	The Netherlands	France	France
Sex	Female	Female	Female	Male	Female	Female
Base change	c.140G>T	c.299C>T	c.814T>C	c.835C>T	c.890G>C	c.1201G>C
Amino acid change	p.Gly47Val	p.Ser100Phe	p.Ser272Pro	p.His279Tyr	p.Arg297Thr	p.Asp401His
Exon	1	1	2	2	3	4
Inheritance	?	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>
Current age (years)	13	6	16	12	15	18
Age at seizure onset (months)	7	10	8	13	8	4
Seizure types	FS, TCS, absences, focal, myoclonic seizures	FS, TCS, CS, absences, focal, myoclonic seizures	FS, CS, focal seizures, absences	FS (atypical), CS, TCS, absences, myoclonic seizures	FS, focal seizures, absences	FS, TCS, absences, focal, myoclonic seizures
<i>Status epilepticus</i>	yes	no	yes	no	yes	yes
ID	Moderate/severe	Moderate	Severe	Mild	Moderate/severe	Moderate/severe
MRI	NA	Normal	Normal	Normal	Normal	Normal
Pharmacoresistance	yes	yes	yes	yes	yes	yes
Behavior and language	Absence of language	Autistic features	Behavioral disturbances, autistic features	Behavioral disturbances; ADHD	Behavioral disturbances, autistic features	Behavioral disturbances, autistic features
Other features	Ataxia	None	Motor delay	Truncal ataxia	None	Polyphagia

FS: febrile seizures, TCS: tonic-clonic seizures, CS: clonic seizures, ID: intellectual disability, ADHD: attention deficit hyperactivity disorder; NA: unavailable

FIGURE LEGENDS




Figure 1 Identification of *HCN1* missense mutations. **(a)** Pedigrees and segregation analysis of the six *HCN1* missense variants identified in this study. The arrows indicate the probands. p.Ser100Phe, p.Ser272Pro, p.Arg297Thr, p.His279Tyr and p.Asp401His were absent from both parents, indicating that they occurred *de novo* in the probands. Segregation analysis could not be performed for the p.Gly47Val variant, because parental DNA samples were not available. **(b)** Schematic diagram of the *HCN1* channel, showing the location of the amino acids affected by the missense mutations identified in this study (stars).




Figure 2 Patch-clamp analysis of the functional impact of the *de novo* hHCN1 mutations. **(a)** Representative traces of whole-cell currents recorded from CHO-K1 cells transfected with pEGFP, reflecting the endogenous current (control), WT, S100F, H279Y, R297T, S272P or D401H hHCN1 channels. The arrow indicates the zero current level. **(b)** Plot of mean current density as a function of test voltage for WT, S100F, H279Y and D401H hHCN1 channels. Current densities did not differ significantly between the WT and mutant channels ($p > 0.05$), except for the D401H mutant (two-way ANOVA, $* p < 0.05$ for voltage -140 mV to -60 mV). **(c)** Mean tail current activation curve for the WT, S100F, H279Y and D401H hHCN1 channels. Red lines show fits of a Boltzmann function providing the half-activation voltage $V_{1/2}$ and slope factor (k) for the WT: -72.06 ± 0.73 mV, $k = 13.1 \pm 0.5$ mV, S100F: -44.59 ± 1.91 mV, $k = 23.9 \pm 1.3$ mV; H279Y: -54.76 ± 1.49 mV, $k = 22.4 \pm 1.1$ mV; D401H: -25.54 ± 0.96 mV, $k = 24.5 \pm 0.8$ mV. **(d)** The D401H and S100F mutant channels had higher activation time constants than the WT hHCN1 channel (one-way ANOVA, $*** p < 0.001$). **(e)** The three mutant channels displayed enhanced deactivation time constants compared with those of the WT hHCN1 (one-way ANOVA, $* p < 0.05$ and $*** p < 0.001$). Data are presented as means \pm SEM, with the numbers of experiments indicated in brackets and SEM indicated by error bars.





Figure 3 Data analysis of co-expression of WT and mutant hHCN1 channels with the patch clamp technique. **(a)** Plot of mean current density as a function of test voltage for CHO-K1 cells transfected with pEGFP, reflecting endogenous current (control), 0.5 μ g WT, 1 μ g WT, WT+S272P, WT+ R297T and WT+D401H hHCN1 channels. Identical amount of WT and mutant cDNA (i.e. 0.5 μ g) were cotransfected. Current density of WT+S100F, WT+S272P, and WT+R297T hHCN1 channels were significantly different compared with current density of WT (1 μ g) channels (two-way ANOVA, *** $p < 0.001$). **(b)** Bar graph of current densities for each experimental group at -140 mV. **(c)** Mean tail current activation curve for 0.5 μ g WT, 1 μ g WT, WT+S272P, WT+R297T, and WT+D401H hHCN1 channels. Red lines show fits of a Boltzmann function (online methods) providing the half-activation voltage $V_{1/2}$ and slope factor (k) for 1 μ g WT: -72.06 ± 0.73 mV, $k = 13.1 \pm 0.5$ mV; 0.5 μ g WT: -75.22 ± 0.91 mV, $k = 14.63 \pm 0.7$ mV; WT+S100F: -69.51 ± 0.99 mV, $k = 20.7 \pm 0.8$ mV, WT+S272P: -70.38 ± 1.68 mV, $k = 27.3 \pm 1.4$ mV; WT+D401H: -62.98 ± 1.33 mV, $k = 20.8 \pm 0.9$ mV. **(d)** The WT+D401H hHCN1 channels had higher activation time constants than the WT channels (one-way ANOVA, * $p < 0.05$). Data are presented as means \pm SEM, with the numbers of experiments given in brackets and SEM indicated by error bars.

Supplementary information



De novo mutations in *HCN1* cause early infantile epileptic encephalopathy

Caroline Nava^{1-4,24}, Carine Dalle^{1,5,24}, Agnès Rastetter¹, Pasquale Striano⁶, Carolien G F de Kovel⁷, Rima Nabbout^{8,9}, Claude Cancès¹⁰, Dorothée Ville¹¹, Eva H Brilstra⁷, Giuseppe Gobbi¹², Emmanuel Raffo¹³, Delphine Bouteiller¹⁴, Yannick Marie¹⁴, Oriane Trouillard^{1,3,4}, Angela Robbiano¹⁵, Boris Keren⁴, Dahbia Agher¹, Emmanuel Roze¹⁻³, Suzanne Lesage¹⁻³, Aude Nicolas¹⁻³, Alexis Brice¹⁻⁴, Michel Baulac¹⁻³, Cornelia Vogt¹⁶, Nady El Hajj¹⁶, Eberhard Schneider¹⁶, Arvid Suls^{17,18}, Sarah Weckhuysen^{17,18}, Padhraig Gormley¹⁹, Anna-Elina Lehesjoki^{20,21}, Peter De Jonghe^{17,18}, Ingo Helbig²², Stéphanie Baulac¹⁻³, Federico Zara¹⁵, Bobby P C Koeleman⁷, EuroEPINOMICS RES Consortium²³, Thomas Haaf¹⁶, Eric LeGuern¹⁻⁴ & Christel Depienne^{1,3,16}

¹INSERM UMR 975, Institut du Cerveau et de la Moelle Epinière, Hôpital Pitié-Salpêtrière, Paris, France. ²CNRS 7225, Hôpital Pitié-Salpêtrière, Paris, France. ³Université Pierre et Marie Curie–Paris 6 (UPMC), UMRS 975, Paris, France. ⁴Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Paris, France. ⁵Institut du Cerveau et de la Moelle Epinière, Plateforme d'Electrophysiologie, Paris, France. ⁶Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, 'G Gaslini Institute', Genova, Italy. ⁷Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. ⁸Department of Pediatric Neurology, Centre de Référence Epilepsies Rares, Hôpital Necker–Enfants Malades, AP-HP, Paris, France. ⁹INSERM U663, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker–Enfants Malades, Paris, France. ¹⁰Service de Neurologie Pédiatrique, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. ¹¹Service de Neurologie Pédiatrique, Hôpital Femme Mère Enfant, Centre Hospitalier Universitaire de Lyon, Bron, France. ¹²Child Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Institute of Neurological Sciences of Bologna, Bologna, Italy. ¹³Service de Neuropédiatrie, Hôpital d'Enfant de Brabois, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France. ¹⁴Institut du Cerveau et de la Moelle Epinière, Plateforme de Génotypage et Séquençage, Paris, France. ¹⁵Laboratory of Neurogenetics, Department of Neurosciences, Gaslini Institute, Genova, Italy. ¹⁶Institut für Humangenetik, Universität Würzburg, Würzburg, Germany. ¹⁷Neurogenetics Group, Department of Molecular Genetics, VIB, Antwerp, Belgium. ¹⁸Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ¹⁹Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. ²⁰Folkhälsan Institute of Genetics, Helsinki, Finland. ²¹Research Programs Unit, Molecular Neurology and Neuroscience Center, University of Helsinki, Helsinki, Finland. ²²Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian Albrechts University, Kiel, Germany. ²³Full lists of members and affiliations appear at the end of the paper. ²⁴These authors contributed equally to this work.




Supplementary Figure 1 Comparison of the mean number of rare variants per base and per individual between *HCN1* and selected genes expressed in the brain. The numbers of truncating variants (nonsense and splice site), rare missense variants (with MAF < 1‰), very rare missense variants (present in fewer than ten individuals) and very rare missense variants predicted to be possibly or probably damaging by Polyphen-2 per base and per individual have been calculated for selected genes expressed in the brain, associated with autosomal dominant epilepsies or epileptic encephalopathies (*SCN1A*, *SCN2A*, *SCN8A*, *SCN1B*, *CHD2*, *STXBP1*, *KCNT1*, *GRIN2A*, *GRIN2B*, *SYNGAP1*), autosomal recessive various phenotypes (*CLCN2*, *EPM2A*, *NHLRC1*, *POLG*, *RELN*) and X-linked epileptic encephalopathy (*PCDH19*) and for genes associated with complex phenotypes (*DRD4*) or no known disorder in humans (*HTR3B*), from data of the European ESP population (Exome Variant Server, <http://evs.gs.washington.edu/EVS/>).




Supplementary Figure 2 Identification of a heterozygous deletion encompassing exon 4 of *HCN1* in a female subject with ID and ASD, inherited from her asymptomatic father. **(a)** Cyto-12 SNP array (Illumina) profiles of the patient with *HCN1* exon 4 deletion and details of the coding sequences included the deletion: the y axis indicates the B allele frequency (above) and the log R ratio (below), and the x axis indicates the position on chromosome 5. The deletion spans ~33 kb and theoretically leads to an in-frame deletion of 73 amino acids (p.Asn338_Lys410del) in the extracellular loop between the S5 and S6 domains containing the pore region. **(b)** Confirmation of the presence of the *HCN1* heterozygous deletion in the proband and her father by quantitative PCR using primers located on exon 4 (forward: 5'-CCACCTGCTATGCCATGTTT-3'; reverse: 5'-ATACTGCCGCCTCGAAGsAAT-3'). RT-PCR experiments were performed using 10 ng of genomic DNA, 0.8 μ M of each primer and 12.5 μ l of SYBR Green PCR master mix (Applied Biosystems) in a total volume of 25 μ l. RNase P (RNase P Control Assay, Applied Biosystems) was used as the reference amplicon. Each sample was run in triplicate on an ABI PRISM 7700 Detection System (Applied Biosystems), and three different experiments were used for final quantification. Relative ratios were calculated using the formula $r = 2^{-\Delta\Delta C_t}$ with $\Delta\Delta C_t = (C_{t \text{ mutation}} - C_{t \text{ RNaseP}})_{\text{ind tested}} - (C_{t \text{ mutation}} - C_{t \text{ RNaseP}})_{\text{ind ref}}$.

	47		100
HCN1_HUMAN	PPGGGGAGAKEHGNSVCFK	HCN1_HUMAN	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_MACAQUE	PPGGGGAGAKEHGNSVCFK	HCN1_MACAQUE	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_ORANGUTAN	PPGGGGAGAKEHGNSVCFK	HCN1_ORANGUTAN	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_MARMOSET	PPGGGGAGAKEHGNSVCFK	HCN1_MARMOSET	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_MOUSE	PPGGG-AAGKEHGNSVCFK	HCN1_MOUSE	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_RAT	PPGGG-AAGKEHGNSVCFK	HCN1_RAT	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_COW	PPGGGGTGAKEHGNSVCFK	HCN1_COW	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_GALAGO	PPGGGGAGAKEHGNSVCFK	HCN1_DOG	QRQFTSMLQPGVKNKFSLRMFGSQK
HCN1_DOG	PPGGGGAGAKELGNSVCFK	HCN1_PANDA	QRQFTSMLQPGVKNKFSLRMFGSQK
		HCN1_RABBIT	QRQFTSMLQPGVKNKFSLRMFGSQK
		HCN1_BIRD	QRQFTSMLQPGVKNKFSLRMFGSQK
		HCN1_CHICKEN	QRQFTSMLQPGVKNKFSLRMFGSQK
		HCN1_FROG	QRQFGSLMQPGVKNKFSLRMFGSQK
		HCN1_TETRAODON	QRQFGAMMQPGVKNKFSLRMFGSQK
	272 279	297	401
HCN1_HUMAN	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_MACAQUE	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_ORANGUTAN	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_MARMOSET	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_MOUSE	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_RAT	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_COW	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_DOG	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_PANDA	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_RABBIT	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_BIRD	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_CHICKEN	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_FROG	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK
HCN1_TETRAODON	LLRLLRLSRLIRYIHQWEEIFHMTYDLASAVVRIFNLI	GMMML	GHATALIQSLDSSRRQYQEKYK


Supplementary Figure 3 Alignment of the regions flanking the six missense variants in orthologous proteins, showing the conservation of the altered amino acids. Multiple pairwise alignments were performed using ClustalW 2.1 (<http://www.genome.jp/tools/clustalw/>). The amino acids altered by the mutations are highlighted. Full alignments including all species are provided as a Supplementary Note.



Supplementary Figure 4 Reversal potential (E_{rev}) of gain-of-function mutations affecting the hHCN1 channel. **(a)** Representative whole-cell current trace recorded from a CHO-K1 cell transfected with construct for wild-type (WT) hHCN1 channel. For determination of E_{rev} , currents were fully activated by a prepulse to -130 mV for 1 s from a holding potential of -20 mV, and test pulses were then applied from -100 mV to $+40$ mV in 10-mV increments, with tail current measured immediately after the prepulse. **(b)** Plot of mean tail current density as a function of test voltage for WT, S100F, H279Y and D401H hHCN1 channels. The number of cells for each condition is indicated in parentheses. The red line represents a linear regression through the mean values for the tail current density and is used to obtain E_{rev} . **(c)** Bar graph of E_{rev} for WT hHCN1 and the three mutant channels (one-way ANOVA followed by a Dunnett's test, $***P < 0.001$). Data are represented as mean values \pm s.e.m. with numbers of experiments given in parentheses.



Supplementary Figure 5 Data analysis of loss-of-function mutations affecting the hHCN1 channel identified with the patch clamp technique. Plot of mean current density as a function of test voltage for control cells (cells transfected only with pEGFP plasmid, reflecting the endogenous current) and cells expressing S272P and R297T mutant channels. The number of cells for each condition is indicated in parentheses. Currents were elicited by test pulses ranging from -140 mV to $+40$ mV in 10-mV increments from a holding potential of -20 mV and were normalized to cell capacitance (representative traces in Fig. 2a). Current densities of both mutant channels were not significantly different compared with endogenous currents from control cells (one-way ANOVA followed by a Dunnett's test, $P > 0.05$). Data are presented as means \pm s.e.m. with numbers of experiments given in parentheses.



Supplementary Figure 6 Impact of *de novo* HCN1 mutations on protein expression and localization at the plasma membrane. **(a)** Semiquantitative analysis of WT and mutant (S100F, S272P, R297T, H279Y or D401H) HCN1 protein expression in whole-cell lysates and at the plasma membrane by protein blot. CHO-K1 cells were transiently cotransfected with 12 μ g of WT or mutant HCN1 expression plasmid using the Neon electroporation system (Invitrogen); 24 h after transfection, proteins present at the plasma membrane were isolated using the Cell Surface Protein Isolation kit (Pierce), following the manufacturer's recommendations. Whole-cell lysates were kept before isolation of membrane protein from the same experiments. Proteins present in both fractions were resolved by SDS-PAGE on 4–12% gradient gels (Invitrogen) and electrotransferred onto nitrocellulose membranes. HCN1 was probed using a monoclonal mouse anti-HCN1 antibody (ab84816, Abcam; 1:10,000 dilution), and the signal was visualized with enhanced chemiluminescence (Pierce). Membranes were probed with anti-Flotillin-1 antibody (610820, BD Biosciences; 1:1,000 dilution) for normalization. The image shows the result of a representative experiment. **(b)** Semiquantitative measurement of WT and mutant HCN1 proteins present in whole-cell lysates (blue) and at the plasma membrane (red) from three independent experiments using the ImageJ program (<http://rsb.info.nih.gov/ij/>). The values obtained for WT and mutant HCN1 proteins were corrected for the intensity of the corresponding flotillin bands. Data are presented as means \pm s.e.m. Note that, although the expression of S100F, S272P and R297T HCN1 channels was similarly decreased, an I_h current was recorded for S100F but nor for S272P and R297T. In addition, the S272P and R297T mutants showed a dominant-negative effect on the WT-mutant heteromeric channels, suggesting that mutant homomeric channels are less stable than WT-mutant heteromeric channels. **(c)** Effect of proteasome inhibition on mutant (S100F, S272P, R297T, H279Y or D401H) HCN1 protein expression in whole-cell lysates. CHO-K1 cells were transiently cotransfected with WT or mutant HCN1 expression plasmids; 24 h after transfection, half of the cells was treated with 1 μ M epoxomicin (E3652, Sigma) for 16 h. Proteins were then resolved by SDS-PAGE on 4–12% gradient gels (Invitrogen) and electrotransferred onto nitrocellulose membranes. HCN1 was probed using the monoclonal mouse anti-HCN1 antibody, and the signal was detected by enhanced direct near-infrared fluorescence detection system (LI-COR Biosciences). Membranes were probed with anti-actin antibody (ab3280, Abcam; 1:4,000 dilution) for normalization. The image shows the result of a representative experiment.

Family number/ Patient ID	6 / N09 2300	2/ DRA-20	3/ N 07 1339	5/ 2008D01179	4/ N10 0713	1/ N06 0565
Patient origin	France	Italy	France	The Netherlands	France	France
Sex	Female	Female	Female	Male	Female	Female
Base change	c.140G>T	c.299C>T	c.814T>C	c.835C>T	c.890G>C	c.1201G>C
Amino acid change	p.Gly47Val	Ser100Phe	p.Ser272Pro	p.His279Tyr	p.Arg297Thr	p.Asp401His
Exon	1	1	2	2	3	4
Inheritance	Unknown	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>
<i>In silico</i> predictions (SIFT / Polyphen-2)	Deleterious / Benign	Deleterious / Possibly damaging	Deleterious / Possibly damaging	Deleterious / Possibly damaging	Deleterious / Possibly damaging	Deleterious / Probably damaging
Age at time of analysis (years)	13	6	16	12	15	18
Age at seizure onset (months)	7	10	8	13	8	4
Seizure type at onset	Febrile, TCS	Febrile and afebrile, TCS	Febrile, hemiclonic	Febrile seizures (atypical)	Febrile, hemiclonic (left / right) seizures	TCS, cyanosis
Seizure types during disease course	TCS, atypical absences with or without myoclonic jerks; focal seizures, seizures in clusters	Clonic seizures, TCS, atypical absences, myoclonic jerks, focal (frontal?) seizures	Clonic seizures, atypical absences, focal seizures	Clonic seizures, TCS, atonic, atypical absences, myoclonic jerks, nocturnal seizures	Hemiclonic seizures, atypical absences, nocturnal frontal seizures, focal seizures, drop attacks	TCS, myoclonic jerks, atypical absences, nocturnal frontal seizures
Febrile seizures	yes	yes	yes	yes	yes	yes
Status epilepticus	yes	no	yes	no	yes	yes

Frequency of seizures	Several per month before 3 years, several per year thereafter	Several per week, clusters	Several per month	Several per week at onset; several per year later on; absences and myoclonic jerks: several days per week	Several per week at onset; seizure-free between the ages of 2 and 6 yrs, with STP,VPA CLB; Rare seizures between 6 and 10 yrs of age; several seizures per week from the age of 10 yrs	Several per week at onset; several absences per day and several nocturnal seizures per month later on
ID	Moderate/severe	Moderate	Severe	Mild	Moderate/severe	Moderate/severe
MRI	NA	Normal	Normal	Normal	Normal	Normal
EEG	NA	GSW	Normal then multifocal spikes, slowing	Diffuse (poly)peakwave complexes; later on: multifocal epileptic discharges with frontocentral maximum	8 months: normal 9 months: diffuse PSW, IPS+ ; 9 yrs: frontal synchronous spike and wave with activation during sleep	PSW
Pharmacoresistance	yes	yes	yes	yes	yes	yes
AEDs	VPA, CLB	LTG, CLB, VPA, PB	VPA, CLB, STP	ETX, LTG	VPA, CLB, STP, TPM, ZNS, LVT, LTG, ketogenic diet, VNS	VPA, CLB, TPM
Behavior and language	Absence of language	Autistic features	Behavioral disturbances, autistic features, stereotypies	Behavioral disturbances; agitation, attention deficit disorder	Behavioral disturbances, autistic features	Autistic features, agitation, aggressiveness, stereotypies
Other features	Ataxia	None	Motor delay	Truncal ataxia	None	Polyphagia

Supplementary Table 1 Detailed genetic and clinical characteristics of the patients with *HCN1* mutations identified in this study.

TCS: tonic-clonic seizures, yrs: years, ID: intellectual disability, AED: antiepileptic drug, VPA: sodium valproate, CLB: clobazam, STP: stiripentol, TPM: topiramate, ZNS: zonisamide, LVT: levetiracetam, LTG: lamotrigine, ETX: ethosuximide, VNS: Vagus Nerve stimulation; GSW: generalized spike waves, PSW: polyspike waves, IPS: intermittent photic stimulation, NA: unavailable.

Population	Chrom	Position	Ref base	Sample base	Gene	Transcript	Transcript Variant	Protein Variant	Number of ind (EA/AA)	Impact	SIFT Prediction	PolyPhen-2 Prediction	RsNumber
PD	5	45696129	C	A	HCN1	NM_021072.3	c.67G>T	p.Ala23Ser	1	missense	Tolerated	Benign	
PD	5	45695967	G	T	HCN1	NM_021072.3	c.229C>A	p.Pro77Thr	1	missense	Tolerated	Benign	
ESP	5	45695964	C	T	HCN1	NM_021072.3	c.232G>A	p.Ala78Thr	0/1	missense	Tolerated	Benign	
ESP	5	45695937	G	A	HCN1	NM_021072.3	c.259C>T	p.Pro87Ser	0/1	missense	Deleterious	Benign	
ESP	5	45695900	G	A	HCN1	NM_021072.3	c.296C>T	p.Thr99Ile	1/0	missense	Tolerated	Benign	rs143865339
ESP	5	45645537	T	C	HCN1	NM_021072.3	c.599A>G	p.Asn200Ser	1/0	missense	Tolerated	Benign	
ESP	5	45645433	T	C	HCN1	NM_021072.3	c.703A>G	p.Ile235Val	1/0	missense	Deleterious	Benign	
ESP	5	45462005	T	G	HCN1	NM_021072.3	c.954A>C	p.Leu318Phe	1/0	missense	Deleterious	Possibly damaging	
ESP	5	45461997	A	G	HCN1	NM_021072.3	c.962T>C	p.Leu321Pro	1/0	missense	Deleterious	Benign	rs149434809
ESP	5	45396611	G	A	HCN1	NM_021072.3	c.1213C>T	p.Arg405Trp	1/0	missense	Deleterious	Probably damaging	
ESP	5	45353327	T	G	HCN1	NM_021072.3	c.1252A>C	p.Met418Leu	1/0	missense	Deleterious	Possibly damaging	
ESP	5	45353314	T	G	HCN1	NM_021072.3	c.1265A>C	p.Lys422Thr	1/0	missense	Deleterious	Probably damaging	rs140166527
ESP	5	45353231	G	A	HCN1	NM_021072.3	c.1348C>T	p.Leu450Phe	1/0	missense	Deleterious	Probably damaging	rs146123836
PD	5	45303809	G	A	HCN1	NM_021072.3	c.1510C>T	p.Arg504*	1	stop gain			
CI	5	45303797	C	T	HCN1	NM_021072.3	c.1522G>A	p.Val508Met	1	missense	Deleterious	Benign	
CI, PD	5	45262760	T	A	HCN1	NM_021072.3	c.1936A>T	p.Thr646Ser	1, 1	missense	Tolerated	Benign	
PD	5	45262715	T	A	HCN1	NM_021072.3	c.1981A>T	p.Arg661Trp	1	missense	Deleterious	Possibly damaging	
ESP	5	45262714	C	T	HCN1	NM_021072.3	c.1982G>A	p.Arg661Lys	0/1	missense	Deleterious	Benign	rs143224211
ESP	5	45262688	C	T	HCN1	NM_021072.3	c.2008G>A	p.Ala670Thr	1/0	missense	Deleterious	Benign	
ESP	5	45262687	G	A	HCN1	NM_021072.3	c.2009C>T	p.Ala670Val	2/1	missense	Deleterious	Benign	rs142280884
ESP	5	45262675	G	A	HCN1	NM_021072.3	c.2021C>T	p.Ser674Phe	0/1	missense	Deleterious	Benign	rs138171983
ESP	5	45262619	T	C	HCN1	NM_021072.3	c.2077A>G	p.Ile693Val	1/0	missense	Tolerated	Benign	
ESP	5	45262591	G	A	HCN1	NM_021072.3	c.2105C>T	p.Ala702Val	3/0	missense	Deleterious	Possibly damaging	rs147007826
ESP	5	45262564	G	A	HCN1	NM_021072.3	c.2132C>T	p.Pro711Leu	0/2	missense	Deleterious	Possibly damaging	
ESP	5	45262526	C	T	HCN1	NM_021072.3	c.2170G>A	p.Ala724Thr	0/6	missense	Deleterious	Possibly damaging	rs141383188
ESP	5	45262387	G	A	HCN1	NM_021072.3	c.2309G>A	p.Ser770Asn	0/1	missense	Deleterious	Benign	
ESP	5	45262375	A	G	HCN1	NM_021072.3	c.2321T>C	p.Leu774Pro	0/2	missense	Deleterious	Possibly damaging	rs149702217
ESP	5	45262321	G	A	HCN1	NM_021072.3	c.2375C>T	p.Ser792Leu	0/1	missense	Deleterious	Probably damaging	rs140758934
PD	5	45262306	A	C	HCN1	NM_021072.3	c.2390T>G	p.Val797Gly	1	missense	Tolerated	Benign	
ESP	5	45262234	C	T	HCN1	NM_021072.3	c.2462C>T	p.Ala821Val	1/0	missense	Tolerated	Benign	
PD	5	45262211	C	A	HCN1	NM_021072.3	c.2485G>T	p.Ala829Ser	1/0	missense	Tolerated	Benign	
ESP	5	45262189	C	T	HCN1	NM_021072.3	c.2507C>T	p.Pro836Leu	1/0	missense	Deleterious	Possibly damaging	
ESP	5	45262137	C	G	HCN1	NM_021072.3	c.2559C>G	p.Asn853Lys	1/0	missense	Tolerated	Benign	rs140186173
ESP	5	45262106	C	T	HCN1	NM_021072.3	c.2590G>A	p.Ala864Thr	0/1	missense	Deleterious	Benign	

ESP	5	45262090	C	T	HCN1	NM_021072.3	c.2606G>A	p.Arg869Lys	0/1	missense	Tolerated	Benign
CI	5	45262037	C	T	HCN1	NM_021072.3	c.2659G>A	p.AlaA887Thr	1	missense	Tolerated	Benign

Supplementary Table 2 Summary of *HCN1* variants present in the ESP population and in cases with Parkinson's disease (PD, $n = 1,407$) and control individuals (CI, $n = 530$) included in the IPDGC study.

A total of 27 missense variants, all in the heterozygous state, in 38 individuals (Frequency of heterozygotes $38/6503=0.0058$) are present in the ESP population. This list does not include the frequent polymorphic in-frame deletions in the glycine stretch (c.199-207delGGTGGCGGC, p.67delGGG; c.214-222delGGCGCGGC, p.72delGGG; c.217-222delGGCGGC, p.73delGG) previously described in exon 1 of *HCN1*.^{23,24}

The frequency of *HCN1* heterozygous variants is identical in two other populations (530 control individuals and 1407 subjects with Parkinson disease) from the International Parkinson's Disease Genomics Consortium (IPDGC) study: $3/530=0.0056$; $7/1407=0.005$, indicating that this observation is reliable. Considering only the variants predicted "possibly or probably damaging" by Polyphen-2, and the regions of *HCN1* that are sufficiently covered by exome sequencing *i.e.* (excluding positions c.1 to c.239, insufficiently covered), the number of heterozygotes in the ESP, PD and control populations is respectively 20, 1 and 0. These numbers are significantly lower than the number of *HCN1* damaging missense variants found in epileptic patients (*i.e.* $5/196$, $p= 0.00067$, $p= 0.0001$ and $p= 0.001$; Exact Fisher test).

Note that one PD patient has a *HCN1* nonsense mutation, further supporting the hypothesis that haploinsufficiency of *HCN1* does not cause EIEE.

Several missense variants present in these control populations are comparable, in terms of predictions, to the mutations identified in patients with EIEE. The existence of apparently or even well-characterized deleterious mutations in individuals from the ESP population is not specific of *HCN1* and is observed for other genes, in particular those involved in human epilepsies. For example, 51 different missense variants predicted to be deleterious are present in *SCN1A* in EVS, including the R1596C mutation in one individual⁴⁸. These observations have several possible grounds: 1) the clinical status of individuals included in the ESP population, in particular the occurrence of epilepsy in subjects with possibly deleterious variants, is unavailable; 2) the presence of the variants/mutations has not been validated and some of these variants might be false-positives or mosaic (*i.e.* present in the blood but not in the brain); 3) rare subjects might have constitutive deleterious mutations without expressing any symptom, possibly due to genetic buffering or other mechanisms.

23. Dibbens, L.M. et al. Augmented currents of an HCN2 variant in patients with febrile seizure syndromes. *Ann Neurol* 67, 542-6 (2010).
24. Tang, B., Sander, T., Craven, K.B., Hempelmann, A. & Escayg, A. Mutation analysis of the hyperpolarization-activated cyclic nucleotide-gated channels HCN1 and HCN2 in idiopathic generalized epilepsy. *Neurobiol Dis* 29, 59-70 (2008).
48. Cherepanova N.S., Leslie E., Ferguson P.J., Bamshad M.J. & Bassuk A.G. Presence of epilepsy-associated variants in large exome databases. *J Neurogenet* 27, 1-4 (2013).

Study	platform	CNV detection	population	Sample	DNA source	Genome version	Chr	CNV type	Gene	Number of ind	start	end	length	Localization/ effect on HCN1	Phenotype
Itsara et al, 2009	Illumina 650Y	HMM	hgdp	HGDP01238	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45339429	45445657	106228	encompasses exons 4 and 5	control subject
Itsara et al, 2009	Illumina 550K	HMM	NINDS-317+240	222	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45361672	45506180	144508	encompasses exons 3 to 5	control subject
Itsara et al, 2009	Illumina 317K	HMM	parc-prince	X	peripheral blood	Hg19	5	Del	HCN1	1	45361672	46322869	961197	encompasses exons 1 to 5	control subject
Itsara et al, 2009	Illumina 550K	HMM	NINDS-550K	1780862470_A	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45400632	45492834	92202	encompasses exon 3	control subject
Itsara et al, 2009	Illumina 317K	HMM	parc-prince	X	peripheral blood	Hg19	5	Del	HCN1	1	45400632	45506180	105548	encompasses exon 3	control subject
Itsara et al, 2009	Illumina 317K	HMM	parc-prince	X	peripheral blood	Hg19	5	Dup	HCN1	1	45442078	46264090	822012	encompasses exons 1 to 3	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA10851	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45383084	20022	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA10851	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45373943	10881	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA15510	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45383084	20022	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	QSNP	5 healthy subjects	NA15510	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45406321	43259	encompasses exon 4	control subject
Pinto et al, 2011	Illumina 1M	cnvPart	5 healthy subjects	NA18517	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45409900	46838	encompasses exon 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA18517	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45366788	45378207	11420	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA18517	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45390738	27676	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA18980	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45409900	46838	encompasses exon 4	control subject

Cooper et al, 2011	CGH	HMM	15,767 children with ID	ND	peripheral blood	Hg19	5	Del	HCN1	3	NA	NA	NA	encompassing coding sequences: 13	Individuals with ID or DD +/- craniofacial defects (n=1)
Cooper et al, 2011	Illumina SNP arrays	HMM	8,329 control subjects	ND	peripheral blood	Hg19	5	Del	HCN1	13	NA	NA	NA		control subjects
Cooper et al, 2011	CGH	HMM	15,767 children with ID	ND	peripheral blood	Hg19	5	Dup	HCN1	9	NA	NA	NA	encompassing coding sequences: 5	Individuals with ID or DD and ASD (n=1) or craniofacial defects (n=4)
Cooper et al, 2011	Illumina SNP arrays	HMM	8,329 control subjects	ND	peripheral blood	Hg19	5	Dup	HCN1	5	NA	NA	NA		control subjects
Nava et al, 2013	Illumina SNP arrays	cnvPart	194 subjects with ASD	PSL_10744	peripheral blood	Hg19	5	Del	HCN1	1	NA	NA	NA	encompasses exon 4	Individual with ID and ASD

Supplementary Table 3 Copy number variants (CNVs) encompassing *HCN1* reported in the literature.

NA: unavailable

HCN1-ex1_F1	TACCCTCTCGGCTACGTGTC
HCN1-ex1_R1	CGTCCACCTTGAAGCACAC
HCN1-ex1_F2	GTCTAACAGCCGGGACGAT
HCN1-ex1_R2	CGGAGGGAGAATTTGTTGAC
HCN1-ex1_F3	TTCATGCAGAGGCAGTTCAC
HCN1-ex1_R3	GAGTGGAGCCTGCTTAGCC
HCN1-ex2_F1	GGGGGATAGGCTGGTTATTTT
HCN1-ex2_R1	GGATGAGATGAAGTCAACCACA
HCN1-ex2_F2	GGACCCCAAAGTGATCAAGA
HCN1-ex2_R2	CATTGCACAGTTGTTTCATTGTA
HCN1-ex3_F	TGCTTACGCTACACAACATCAA
HCN1-ex3_R	TTTTGGCACAACGTTGAAAA
HCN1-ex4_F	GCCATCCTAATGGCTCAGTC
HCN1-ex4_R	CTGGTTAAAGACATTGGCGATA
HCN1-ex5_F	TGATTTCTGATACACCCTAACAATG
HCN1-ex5_R	AGGTTTTTCTTTAGAGTAACGTGGA
HCN1-ex6_F1	TTCAGCATGTTTTTCTTCCAGA
HCN1-ex6_R1	TTTTACCCACGGCTCCTTC
HCN1-ex6_F2	CGGAAACTGGTGGCTACAAT
HCN1-ex6_R2	CTGACATGCTGACATCTCCAA
HCN1-ex7_F	TCAAACAAGTCATTCTTCTTTGTTG
HCN1-ex7_R	ATGAGTCACCACTCCCCACT
HCN1-ex8_F1	GCGTTGTCATCAGTCATTGG
HCN1-ex8_R1	TGGAGATTGTGTCCTCATGC
HCN1-ex8_F2	TGACAACCCTGAATTCCACA
HCN1-ex8_R2	GACTGCTGTACCTGCTGCTG
HCN1-ex8_F3	CCGCTCGAACTTTCCACTATG
HCN1-ex8_R3	TCACGGGTTGAGGGATGG
HCN1-ex8_F4	CTCTGATTTCCAGACCTCATCC
HCN1-ex8_R4	TGAGAGTATTTCTTTCTGCTTTGACA

Supplementary Table 4 Primers used to amplify the coding regions of *HCN1*.

Supplementary Note Full alignments of HCN1 orthologous and paralogous sequences.

(a)

```

HCN1_HUMAN      MEGGGKPNSSNSRDDGNSVFPKASATGAGPAAAEEKRLGTPPGGGGAGAKEHGNSVCFK
HCN1_MACAQUE    MEGGGKPNSSNSRDDGNSVFPKASATGAGPAAAEEKRLGTPPGGGGAGAKEHGNSVCFK
HCN1_ORANGUTAN  MEGGGKPNSSNSRDDGNSVFPKASATGAGPAAAEEKRLGTPPGGGGAGAKEHGNSVCFK
HCN1_MARMOSET   MEGGGKSNSSNSRDDGNSVFPKASATGAGPAAAEEKRLGTPPGGGGAGAKEHGNSVCFK
HCN1_MOUSE      MEGGGKPNASNSRDDGNSVFPKAPATGP---VAADKRLGTPPGGGGAAGKEHGNSVCFK
HCN1_RAT        MEGGGKPNASNSRDDGNSVFPKAPATGP---AAADKRLGTPPGGGGAAGKEHGNSVCFK
HCN1_SQUIRREL   -----XCXFKVD
HCN1_HORSE      -----
HCN1_COW        MEGGGKPNSSNSRDDGNSVFPKAPATGAGPAAAEEKRLGTPPGGGGTGAKEHGNSVCFK
HCN1_GALAGO     MEGGGKPNSSNSRDDGNSVFSKAPAAASAGPAGAEKRLGTPPGGGGAGAKEHGNSVCFK
HCN1_DOG        MEAGGKPNASNSRDDGSSAFP GKAPATGAGPAAAEEKRLGTPPGGGGAGAKELGNSVCFK
HCN1_PANDA      -----
HCN1_RABIT      -----
HCN1_PLATYPUS   -----
HCN1_BIRD       -----GGGSGGVKEHGNSVCFK
HCN1_CHICKEN    -----MEGGKRSSSPGSRDEGSANAFP GKQATPVEKAQSSPGGGAKEHGNSVCFK
HCN1_ANOLE      -----MEGSKPSSSPGSRDEGSPGANACFQGKAEKAPGSPGASGLKEHANSVCFK
HCN1_FROG       -----LPSMESKFNSSTNSSRDDGNNVLQKAEKSLTASTSSVKEHGNSVCFK
HCN1_PIG        -----MATASSPPRRRRARGRQRPRSAWAPRRGAAGPARRS
HCN1_TILAPIA    -----MEDKSNSFSSNKE-EKADGNNVFQRQDSIQKNNTGSQNMK--DHGNSVGFK
HCN1_PLATYFISH  -----MEDKSNSFSSNKE-EKADGNNVFQRQDSIQKNNTGSQNTK--DHGNSVGFK
HCN1_TETRAODON  -----GSQNTK--EHSNSVGFK
HCN1_TROUT      -----MEDKSNSFSSNKEGEGKADGNNVFQRQDSIQKNMGSQNMKGGDHGNSVGFK

```

```

HCN1_HUMAN      VDGGGGGGGGGG--GEEPAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_MACAQUE    VDGGGGGGGG--EEPAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_ORANGUTAN  VDGGGGGEE-----PAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_MARMOSET   VDGGGGGGGGGG--EEPAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_MOUSE      VDGGG-----GEEPAGSFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_RAT        VDGGG-----GEEPAGSFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_SQUIRREL   GGGGG-----GEEPAGSFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_HORSE      -----
HCN1_COW        VDGGGGGGGE-----ESAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_GALAGO     VDGGGGGAE-----ESAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_DOG        VDGGGAGEE-----PAGGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_PANDA      -----GFMQRQFSTMLQPGVKNFSLRMFGSQK
HCN1_RABIT      ----MATASSPPR--RPRRARGLEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_PLATYPUS   -----
HCN1_BIRD       VDGGGGGEEP-----AVGFEDAEGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_CHICKEN    VDGGGAEEP-----VVGFEDEAGPRRQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_ANOLE      VDGGGAAGEEVPVAGLDDPDAARRQQQQQQYGFMRQRFSTMLQPGVKNFSLRMFGSQK
HCN1_FROG       TDAADDPVVG-----FEDAEGPSRPHGFMQRQFGSLMQPGVKNFSLRMFGSQK
HCN1_PIG        TATPCASRWTA AAAVAARSRPGASRRTRRPGGSTASCSGSHLYAAAWGQQLP PHVWEPE
HCN1_TILAPIA    GEREETMVG-----FDDLEGASRQYGFMRQRF GAMMQPGVKNFSLRMFGSQK
HCN1_PLATYFISH  GEREEMVG-----FDDLDGASRQHGFMRQRF GAMMQPGVKNFSLRMFGSQK
HCN1_TETRAODON  GEREEMVG-----FDDLEGASRQHGFMRQRF GAMMQPGVKNFSLRMFGSQK
HCN1_TROUT      GDREALVG-----FDDIDGSGNRHGFMRQRF GAMMQPGVKNFSLRMFGSQK

```

```

HCN1_HUMAN      AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_MACAQUE    AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_ORANGUTAN  AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_MARMOSET   AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_MOUSE      AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_RAT        AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_SQUIRREL   AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_HORSE      -----RFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_COW        AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_GALAGO     AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_DOG        AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_PANDA      AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_RABIT      AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_PLATYPUS   -----MLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_BIRD       AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_CHICKEN    AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_ANOLE      AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_FROG       AVEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_PIG        GGEKEQERVKTAGFWI IHPYSDFRFYDWLIMLIMMVGNLVI IPVGITFFTEQTTTPWII F
HCN1_TILAPIA    AVEKEQERVQTAGYWI IHPYSDFRFYDWLIMLIMMVGNLII IPVGITFFTEQTTTTLV F

```

HCN1_PLATYFISH AVEKEQERVQTAGYWI IHPYSDFRFYDLDLIMMGNLI IIPVGITFFSEQTTTTWLVF
HCN1_TETRAODON AVEKEQERVQTAGYWI IHPYSDFRFYDLDLIMMGNLI IIPVGITFFSDQNTTTWLVF
HCN1_TROUT AVEKEQERVQTAGYWI IHPYSDFRFYDLDLIMMGNLI IIPVGITFFSEQTTTTWLIF
**:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:

HCN1_HUMAN NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_MACAQUE NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_ORANGUTAN NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_MARMOSET NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_MOUSE NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_RAT NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_SQUIRREL NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_HORSE NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_COW NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_GALAGO NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_DOG NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_PANDA NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_RABIT NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_PLATYPUS NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_BIRD NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_CHICKEN NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_ANOLE NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_FROG NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_PIG NVASDTVFLLDLIMNFRGTGVNEDSSEI ILDPKVIKMNLYKSWFVVDFISSIPVDYIFLI
HCN1_TILAPIA NVASDTIFLVDLVMNFRGTGIVNEESSEI ILDPKVIKMNLYKSWFVVDFLSSIPVDYIFLI
HCN1_PLATYFISH NVASDTIFLVDLVMNFRGTGIVNEESSEI ILDPKVIKMNLYKSWFVVDFLSSIPVDYIFLI
HCN1_TETRAODON NVASDTIFLVDLVMNFRGTGIVNEESSEI ILDPKVIKMNLYKSWFVVDFLSSIPVDYIFLI
HCN1_TROUT NVASDTIFLVDLVMNFRGTGIVNEESSEI ILDPKVIKMNLYKSWFVVDFLSSIPVDYIFLI
*****:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:

HCN1_HUMAN VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_MACAQUE VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_ORANGUTAN VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_MARMOSET VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_MOUSE VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_RAT VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_SQUIRREL VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_HORSE VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_COW VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_GALAGO VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_DOG VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_PANDA VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_RABIT VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_PLATYPUS VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_BIRD VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_CHICKEN VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_ANOLE VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_FROG VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_PIG VEKGMDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_TILAPIA VEKGFDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_PLATYFISH VEKGFDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_TETRAODON VEKGFDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
HCN1_TROUT VEKGFDSVEYKTARALRIVRFTKILSLLRLLRSLRLIRYHQWEEIFHMTYDLASAVVRI
****:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:

HCN1_HUMAN FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_MACAQUE FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_ORANGUTAN FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_MARMOSET FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_MOUSE FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_RAT FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_SQUIRREL FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_HORSE FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_COW FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_GALAGO FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_DOG FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_PANDA FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_RABIT FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_PLATYPUS FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNGMVNDFYGTGYALVVFVKMCFMVP
HCN1_BIRD FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNGMVNDFYGTGYALVVFVKMCFMVP
HCN1_CHICKEN FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNGMVNDFYGTGYALVVFVKMCFMVP
HCN1_ANOLE FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNGMVNDFYGTGYALVVFVKMCFMVP
HCN1_FROG FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNGMVNDFYGTGYALVVFVKMCFMVP
HCN1_PIG FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC
HCN1_TILAPIA FNLIGMMLLLCHWDGCLQFLVPLLQDFPPDCWVSLNGMVNDFYGTGYALVVFVKMCFMVP

HCN1_PLATYFISH	FNLIGMMLLLCHWDGCLQYLVLPLQDFPPDCWVSLNGMVNVSWGKQYSYALFKAMSHMLC
HCN1_TETRAODON	FNLIGMMLLLCHWDGCLQYLVP-LQDFPPDCWVSLNGMVNVSWGKQYSYALFKAMSHMLC
HCN1_TROUT	FNLIGMMLLLCHWDGCLQFLVPLQDFPQDCWVSLNGMVNDSWGKQYSYALFKAMSHMLC
	*****:*** **:* . **** :** :* . :** .**
HCN1_HUMAN	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_MACAQUE	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_ORANGUTAN	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_MARMOSET	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_MOUSE	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_RAT	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_SQUIRREL	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_HORSE	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_COW	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_GALAGO	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_DOG	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_PANDA	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_RABIT	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_PLATYPUS	VKCLLPASVSEGSVLLTTLTSLALHTPPFFLYDSSFLGHSWGWLSNLENSEKEFNIKEYKQV
HCN1_BIRD	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_CHICKEN	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_ANOLE	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_FROG	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_PIG	IGYGAQAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_TILAPIA	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_PLATYFISH	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_TETRAODON	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
HCN1_TROUT	IGYGARAPVMSDDLWITMLSMIVGATCYAMFVGHATALIQSLD----SSRRQYQEKYKQV
	: * . ** . . : : * ** : . . : . . * . * . : : : ****
HCN1_HUMAN	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_MACAQUE	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_ORANGUTAN	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_MARMOSET	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILSELNDPLREEIVNFNCRKLVATMP
HCN1_MOUSE	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILSELNDPLREEIVNFNCRKLVATMP
HCN1_RAT	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILSELNDPLREEIVNFNCRKLVATMP
HCN1_SQUIRREL	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_HORSE	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_COW	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_GALAGO	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREXXXNFNCRKLVATMP
HCN1_DOG	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_PANDA	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_RABIT	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_PLATYPUS	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_BIRD	EQYMSFHKLPAEMRQKIHDIYEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_CHICKEN	EQYMSFHKLPAEMRQKIHDIYEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_ANOLE	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEEDSILNELNDPLREEIVNFNCRKLVATMP
HCN1_FROG	EQYMSFHKLPSDMRQKIHDIYEHRYQGKIFDEDNILNELNDPLREEIVNFNCRKLVATMP
HCN1_PIG	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILNELNDPLREEIVNFNCRKLVATMP
HCN1_TILAPIA	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEENILSELNDPLKEEIVNFNCRKLVATMP
HCN1_PLATYFISH	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEDNILSELNDPLKEEIVNFNCRKLVATMP
HCN1_TETRAODON	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEDNILSELNDPLKEEIVNFNCRKLVATMP
HCN1_TROUT	EQYMSFHKLPAADMQRQIHDYIEHRYQGKIFDEDNILSELNDPLKEEIVNFNCRKLVATMP
	*****:*****: . ** *****:* *****
HCN1_HUMAN	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_MACAQUE	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_ORANGUTAN	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_MARMOSET	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_MOUSE	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_RAT	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_SQUIRREL	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_HORSE	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_COW	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_GALAGO	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_DOG	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_PANDA	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_RABIT	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_PLATYPUS	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_BIRD	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSNKELKLT
HCN1_CHICKEN	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSNKELKLT
HCN1_ANOLE	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_FROG	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_PIG	LFANADPNFVTAMLSKLRFEVFPQGDYIIREGAVGKKMYFIQHGAVGVI TKSSKEMKLT
HCN1_TILAPIA	LFANADPNFVTGMLSKLRFEVFPQNDYIIREGTVGKKMYFIQHGAVSVITKFNKEMKLT

HCN1_PLATYFISH LFANADPNFVTGMLSKLKFVFPNDYI IREGTVGKKMYFI QHGVSIVITKFNKEMKLTLD
HCN1_TETRAODON LFANADPNFVTGMLSKLKFVFPNDYI IREGTVGKKMYFI QHGVASVITKSNKEMKLTLD
HCN1_TROUT LFANADPNFVTGMLSKLKFVFPNDYI IREGTVGKKMYFI QHGVASVITKLNKEMKLTLD
***** . ***** : ***** . ***** : ***** . ***** . ***** . ***** : *****

HCN1_HUMAN GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_MACAQUE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_ORANGUTAN GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_MARMOSET GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_MOUSE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_RAT GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_SQUIRREL GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_HORSE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_COW GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_GALAGO GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_DOG GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_PANDA GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_RABIT GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_PLATYPUS GSYFGAEICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_BIRD GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_CHICKEN GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_ANOLE GSYFG-EICLLTKGRRRTASVKADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_FROG GSYFG-EICLLTKGRRRTASVRAETYCRLYSLSVENFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_PIG GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSVDNFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_TILAPIA GSYFG-EICLLTKGRRRTASVRADTYCRLFSLSVDHFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_PLATYFISH GSYFG-EICLLTKGRRRTASVRADTYCRLFSLSVDHFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_TETRAODON GSYFG-EICLLTKGRRRTASVRADTYCRLFSLSVDHFNEVLEEYPMRRRAFETVAIDRLDR
HCN1_TROUT GSYFG-EICLLTKGRRRTASVRADTYCRLFSLSVDHFNEVLEEYPMRRRAFETVAIDRLDR
***** : ***** : ***** : ***** : ***** : ***** : ***** : *****

HCN1_HUMAN IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_MACAQUE IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_ORANGUTAN IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_MARMOSET IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_MOUSE IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_RAT IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_SQUIRREL IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_HORSE IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_COW IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_GALAGO IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_DOG IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_PANDA IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_RABIT IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_PLATYPUS IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_BIRD IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_CHICKEN IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_ANOLE IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_FROG IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_PIG IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_TILAPIA IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_PLATYFISH IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_TETRAODON IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
HCN1_TROUT IGKKNSILLQKFQKDLNTGVFNQENE ILKQIVKHDREMVQAIAP-----
** . * : *

HCN1_HUMAN -----INYPQMTTLNSTSSTTTPTSRM
HCN1_MACAQUE -----INYPQMTTLNSTSSTTTPTSRM
HCN1_ORANGUTAN -----INYPQMTTLNSTSSTTTPTSRM
HCN1_MARMOSET -----INYPQMTTLNSTSSTTTPTSRM
HCN1_MOUSE -----INYPQMTALNCTSSSTTTPTSRM
HCN1_RAT -----INYPQMTALNCTSSSTTTPTSRM
HCN1_SQUIRREL -----INYPQMTALNCTSSSTTTPTSRM
HCN1_HORSE -----INYPQMTALNCTSSSTTTPTSRM
HCN1_COW -----LNYPQMTALNCTSSSTTTPTSRM
HCN1_GALAGO -----INYPQMTALNSTASTTTPTSRM
HCN1_DOG -----INYPQMTALNSTSSTATPTCRA
HCN1_PANDA -----INYPQMTALNSASSTTTPTSRM
HCN1_RABIT -----ISYPQMTALNSTSSTATPTSRM
HCN1_PLATYPUS -----ANYSQMPSLNSSASTTLQSSRL
HCN1_BIRD -----VSLQQMPALN--SSTAA--SSRG
HCN1_CHICKEN -----VSLQQMPALNSSSSTTS--SSRV
HCN1_ANOLE -----VLLQQMPALN----SATASAM
HCN1_FROG -----VSYQQPALN---SSTSSSLRM
HCN1_PIG -----
HCN1_TILAPIA GMNSTPMSGNSIINSPAQPPFSTAFGTTQLQQSSVPLTYSASAIANASAARMMPAAAVAA

HCN1_PLATYFISH TAAAAS-----AAQQQVPSQQRGD-IHKSTQALQSGSLSRDVRHLSASQPSLPHD
 HCN1_TETRAODON -----ASATASAPSPQQRGD-IPKGAQALQSGSLSRDVRHLSASQPSLPHE
 HCN1_TROUT AASSATQQ-----PQQQQVPSQQRSDSLHKASHALQSGSLSRDVRHLSASQPSLPHD

HCN1_HUMAN VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_MACAQUE VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_ORANGUTAN VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_MARMOSET VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_MOUSE VSTLISRPHPTVGESLASIPQPVAAVHSTGLQAGSRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_RAT VSTMISRPHPTVGESLASIPQPVAAVHSTGLQAGSRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_SQUIRREL VSTLISRPHPTVGESLASIPQPVAAVHSTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_HORSE VSTLISRPHPTVGESLASIPQPVTAVHGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_COW VSTLISRPHPTVGESLASIPQPVTAVHGTGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_GALAGO VSTLISRPHPTVGESLASIPQPVTAVPGPGLQAAGRSSVPQRVTLFRQMSSGAIPPNRGV
 HCN1_DOG VATLMSRPHPTVGESLASIPQPVTAVHGPGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGA
 HCN1_PANDA VSTLISRPHPTVGESLASIPQPVAHVHGPGLQAGGRSTVPQRVTLFRQMSSGAIPPNRGA
 HCN1_RABIT VSTLISRPHPTVGESLASIPQPVAHVHSTGLQAAGRSTVPQRVTLFRQMSSGAIPPNRGV
 HCN1_PLATYPUS VSTPISRPHPTVGESLASLPQPASGAQAAGFQAGSRGVSPPRVTLFRQMSSGAIPPHRGV
 HCN1_BIRD ISTLIARPHPTVGESLASLPQPAPGP---GVPPGGRAGVPQRVSLFRQMSSGAIPPHRAA
 HCN1_CHICKEN ISTLIARPHPTVGESLASLPQPAPGT---SVPPASRATVPQRVSLFRQMSSGAIPPNRGA
 HCN1_ANOLE ISMMIARPHPTVGESLASIPQPLSGFQSTGLQAGNKGTVPQRVALFRQMSSGAIPPTRGA
 HCN1_FROG ISTLGSKPHTVGESLASLPQPI SNVQAAGTQSGSRSNIPPRVALFRQMSSGALPPARVG
 HCN1_PIG -----
 HCN1_TILAPIA TSLGPRVHPTSGDSLASIVPPTAAVIQGMNLQSGIRTTVPQRVNLFRQMSSGALPPVRS
 HCN1_PLATYFISH TSLGPRVHPTSGDSLASIVPPTAAVIQGMNLQSGIRTTVPQRVNLFRQMSSGALPPVRS
 HCN1_TETRAODON ASLGPRVHPTSGDSLASIVPPTAAVIQGMNLQSGIRTTVPQRVNLFRQMSSGALPPVRS
 HCN1_TROUT TSLGPRVHPTSGDSLASIVPPTAAVIQGMNLQSGIRTTVPQRVNLFRQMSSGALPPVRAV

HCN1_HUMAN PPAPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
 HCN1_MACAQUE PPAPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
 HCN1_ORANGUTAN PPAPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
 HCN1_MARMOSET PPAPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
 HCN1_MOUSE PPAPP--PAAVQRES-----PSVLNT--DPDAEKPRFASNL
 HCN1_RAT PPAPP--PAAVQRES-----PSVLNK--DPDAEKPRFASNL
 HCN1_SQUIRREL PPAPPPAAALQREP-----SSVLNT--DPDAEKPRFASNL
 HCN1_HORSE PPAPPPAAALPRES-----SSVLST--DPDAEKPRFASNL
 HCN1_COW PPAPPPAAALHREA-----PSVLTT--DSEAEKPRFASNL
 HCN1_GALAGO PPAPPPAAALQREA-----SSVLNT--DPEAEKPRFASNL
 HCN1_DOG PPAPPPAAALPRES-----SSVLTT--DPEAEKPRFASNL
 HCN1_PANDA PPAPPPAAALPRES-----SSVLTT--DPEAEKPRFASNL
 HCN1_RABIT PPAPPPAAALQREA-----SSVLNT--DPEAEKPRFASNL
 HCN1_PLATYPUS VPPGPPTGAPLQRDT-----SGVLNA--EPEGDKPRFASNL
 HCN1_BIRD APPAAPLQKIGRAVQ-----QECRDRYRMPEGDKPRFASNL
 HCN1_CHICKEN VPPAAPLPRDSSAVL-----STE-----PEGDKPRFASNL
 HCN1_ANOLE APSAATLQRDSSTVL-----NTELEG-----DKPRFASNL
 HCN1_FROG ATTQPSAPPTKDSS-----TVSSTDT---DTDKLKYASNL
 HCN1_PIG -----
 HCN1_TILAPIA AAAAAAAAAVAASSSSTQHRDSPGSRSDSVLSSSTETE QDKMRFASNL
 HCN1_PLATYFISH ASAVAAVAAASSSTS-TQHRESPGSRSDSVLSSSTETE QDKMRFASNL
 HCN1_TETRAODON AAAAAAAAAASSVSSS-----STQQSTETE QDKLRFSSNL
 HCN1_TROUT SSAAQHRDSTGSRD-----SRRDSTLSSTETE QDKMRFASNL

(b)

HCN3_HUMAN -----
 HCN4_HUMAN MDKLPSPMRKRLYSLPQQVGAKAWIMDEEEDAE EEGAGGRQDPSRRSIRLRPLPSPSPSA
 HCN2_HUMAN -----MDARGGGGRPGESPGATPAPGPPPPPPAPPQQQP
 HCN1_HUMAN -----

HCN3_HUMAN -----
 HCN4_HUMAN AAGGTESSALGAADSEGPARGAGKSSSTNGDCRRFRGSLASLGSRRGGSGGTGSGSSHG
 HCN2_HUMAN PPPPPAPP PGPAPPQHPRAEALPPEAADEGGPRGLRSDSSCGRPGTPGAASTAK
 HCN1_HUMAN -----MEGGGKPNSSNSRDDGNSVFPKASATG

HCN3_HUMAN -----MEAEQRPAAGASEGATPGLEAVPPVAPPATAASGPIPKSGP
 HCN4_HUMAN HLHDSAEERLLIAEGDASPGEDRTPPGLAAEPERPGASAQPAASPPPPQPPQPPASASCE
 HCN2_HUMAN GSPNGECGRGEPQCSAPGEPARGPKVFSFCRGAASGPAPGPGPAEEAGSEEAGPAGEP
 HCN1_HUMAN AGPAAAEKRLGTPPGGGAGAKAEHGNVCFKVDGGGGGGGGGGGEEEPAGGFEDAEGPRR


```

HCN1_HUMAN -----
HCN3_HUMAN -----RGPLPLSPDSPATLLARSAWRSAGSPASPLV
HCN4_HUMAN LPPPPSSRSPSSSPGQLGQPPGELSLGLATGPLSTPETPPRQPEPPSLVAGASGGASPVG
HCN2_HUMAN -----PLALGSPRLVRRPPPGPAPAAAASPGPPPP
HCN1_HUMAN -----QQVQQSQPPQTQPQQPSPQPQTPGSSTPKN
                               : . : . . *

HCN3_HUMAN PVRAGPWASTSRLPAPPARTLHASLSRAGRSQVSLLGPPP-----
HCN4_HUMAN FTPRGGLSPPGHSPGPPRTFPSAPPRASGSHGSLLLPPASSPPPPQVPQRRGTPPLTPGR
HCN2_HUMAN ASPPGAPASPRAPRTSPYGGLPAAPLAGPALPARRLSRAS-----
HCN1_HUMAN EVHKSTQALHNTNLTREVRPLSASQPSLPHEVSTLISRPHTV-----
          . : * . : .

HCN3_HUMAN -----GGGGRRLGPR
HCN4_HUMAN LTQDLKLISASQPALPQDGAQTLRRASPHSSGESMAAFPLFPRAGGGSGGSGSSGGLGPP
HCN2_HUMAN -----RPLSASQP
HCN1_HUMAN -----ESLASIPQPVTAVPGTGL

HCN3_HUMAN GRPLSASQPSLPQRATGDGSPGRKGSERLPPSGLLAKPPRTAQPPRPPVPEPATPRGL
HCN4_HUMAN GRPYGAIPGQHVTLPKRTSSGSLPPLSLFGARATSSGGPPLTAGPQREPGARPEPVRSK
HCN2_HUMAN SLPHGAPGPAASTRPASSSTPRLGPTPAARAAAAPSPDRRDSASPGAAGGLDPQDSARSRL
HCN1_HUMAN QAGGRSTVPQRVTLFRQMSSGAIPPNRGVPPAPPPPAALPRESSESVLNTDPDAEKPRFA
          : . : . . . . .

HCN3_HUMAN QLSANM
HCN4_HUMAN LPSNL-
HCN2_HUMAN SSNL--
HCN1_HUMAN SNL---

```

Multiple pairwise alignments of HCN1 orthologous (a) and paralogous (b) sequences were performed using Clustalw 2.1 (<http://www.genome.jp/tools/clustalw/>). The amino acids altered by the mutations are highlighted.